Our Story

KBP Biosciences is a global, clinical stage biopharmaceutical company focused on the development of an
innovative pipeline of new chemical entities with known mechanisms of action targeting underserved
patient populationsin organ protection and infectious diseases.

KBP utilizes an integrated discovery and development platform that enables the Company
to efficiently bring new therapies from bench to patients around the world.

Our lead product candidate, KBP-5074, is a third-generation non-steroidal mineralocorticoid receptor
antagonist (MRA) with a potentially best-in-class safety and efficacy profile. It is in clinical developmentfor
the treatment of uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic
Kidney Disease (CKD) patients who have high risk of hyperkalemia.

Global Footprint

Our Leadership

  • Senior Management
  • |
  • Board of Directors
  • |
  • Scientific Advisors
Zhenhua Huang, Ph.D./M.B.A.
Founder and Executive Chairman
Fred Yang, Ph.D.
Chief Development Officer
Julia Yang, Ph.D., M.B.A.
Chief Operating Officer
James McCabe, M.D.
Vice President, Clinical and Medical Affairs
David Hauser, Ph.D.
Vice President, Clinical Project Management
Jay (Xu-Jie) Zhang, Ph.D.
China President
Robert Chen, CPA, MPA
Vice President, Risk management and Compliance
Chris Benson, CPA
Finance Controller
Vincent J. Benn, Ph.D., M.B.A.
Vice President, Regulatory & Medical Affairs
Pengfei Guo (Murphy), Ph.D.
Vice President of CMC
Judy Tan
Vice President, PM and R&D Coordination
Richard Alexander McGregor, Ph.D.
Director of Business Development
Fran Newark
Associated Director of clinical Operations

Our Impact

At KBP Biosciences we are dedicated to push the boundaries of science to transform the lives patients around the world.
We are dedicated to delivering value to our communities, our employees, and the environment.

We are responsible for our actions on people and the planet. We are also mindful of our social responsibilities,
and committed to high standards of governance.